Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MaxCyte, Inc
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 06, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
July 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
May 29, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 07, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 10, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 12, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 04, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 09, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
January 30, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
January 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
ASX:IMU
MXCT
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
January 08, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
January 02, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 11, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 16, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 08, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
October 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Baird Global Healthcare Conference
September 05, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
August 09, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
August 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
July 13, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
July 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 06, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Participate in Upcoming Investor Conferences
June 01, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 10, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
May 04, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 12, 2023
From
MaxCyte, Inc
Via
GlobeNewswire
Tickers
MXCT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.